Profile data is unavailable for this security.
About the company
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.
- Revenue in USD (TTM)51.64bn
- Net income in USD12.45bn
- Incorporated1996
- Employees105.00k
- LocationNovartis AGLichtstrasse 35BASEL 4056SwitzerlandCHE
- Phone+41 613241111
- Fax+41 613247826
- Websitehttps://www.novartis.com/
Mergers & acquisitions
| Acquired company | NOVN:VTX since announced | Transaction value |
|---|---|---|
| Takeda Pharmaceutical Co Ltd-Xiidra 5% Business | 1.19% | 5.30bn |
| IFM Tre Inc | -12.36% | 1.58bn |
| CELLforCURE SASU | -0.78% | -- |
| Endocyte Inc | -0.40% | 2.09bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 19.05bn | 991.29m | 54.72bn | 27.23k | 22.39 | 1.16 | 15.79 | 2.87 | 171.88 | 171.88 | 2,174.39 | 3,318.53 | 0.2333 | 1.10 | 3.61 | -- | 1.21 | 1.36 | 1.48 | 1.77 | 68.54 | 69.83 | 5.20 | 3.83 | 0.822 | 1.86 | 0.5269 | 244.27 | 18.45 | 4.39 | -41.61 | 0.4586 | 11.30 | 0.00 |
| Bayer AG | 48.50bn | 1.10bn | 59.26bn | 116.43k | 53.24 | 1.11 | 10.47 | 1.22 | 1.07 | 1.06 | 45.08 | 51.38 | 0.4228 | 2.27 | 3.65 | 371,485.00 | 0.9738 | 4.12 | 1.19 | 5.28 | 55.46 | 58.83 | 2.30 | 8.16 | 0.9216 | 3.47 | 0.4671 | 69.67 | 13.05 | -0.286 | -47.83 | -11.87 | 3.75 | 6.26 |
| Novartis AG (ADR) | 51.64bn | 12.45bn | 210.49bn | 105.00k | 15.56 | 4.07 | 11.01 | 4.08 | 5.31 | 5.27 | 22.06 | 20.33 | 0.3777 | 2.47 | 6.25 | 412,580.60 | 9.11 | 6.81 | 13.18 | 8.41 | 69.03 | 66.55 | 24.12 | 17.42 | 0.8324 | 40.77 | 0.3927 | 74.61 | 6.05 | 0.1702 | 65.02 | 6.53 | -0.1366 | 3.89 |
| Roche Holding Ltd. | 56.25bn | 10.35bn | 227.32bn | 94.44k | 21.86 | 8.23 | 15.94 | 4.04 | 12.17 | 12.21 | 66.10 | 32.33 | 0.7326 | 2.34 | 5.87 | 601,914.40 | 13.96 | 12.82 | 20.69 | 19.05 | 71.07 | 71.15 | 19.05 | 18.76 | 1.11 | 44.73 | 0.382 | 75.82 | 6.65 | 3.97 | 19.61 | -1.28 | 18.77 | 2.21 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Mar 2019 | 36.34m | 1.43% |
| PRIMECAP Management Co.as of 31 Mar 2019 | 23.86m | 0.94% |
| Franklin Mutual Advisers LLCas of 31 Mar 2019 | 14.02m | 0.55% |
| Fidelity Management & Research Co.as of 31 Mar 2019 | 8.03m | 0.32% |
| Fisher Asset Management LLCas of 31 Mar 2019 | 7.82m | 0.31% |
| Loomis, Sayles & Co. LPas of 31 Mar 2019 | 7.01m | 0.28% |
| UBS Financial Services, Inc.as of 31 Mar 2019 | 7.01m | 0.28% |
| Boston Partners Global Investors, Inc.as of 31 Mar 2019 | 6.46m | 0.25% |
| Managed Account Advisors LLCas of 31 Mar 2019 | 6.38m | 0.25% |
| Brown Brothers Harriman & Co. (Investment Management)as of 31 Mar 2019 | 6.15m | 0.24% |
